. Author manuscript; available in PMC: 2010 Apr 27.

Published in final edited form as: Arch Intern Med. 2009 Apr 27;169(8):750–756. doi: 10.1001/archinternmed.2009.39

Table 3.

Results of Survival Models for Patients Newly Treated with Antidepressants^a,^b

Therapy Disruption Six Months Following Initiation	Adjusted Hazard Ratio		Change in Michigan vs. Indiana Risk Ratios
	Policy vs. Pre-Policy Hazard (95% CI)^c
	Michigan (N=3,671)	Indiana (N=2,400)
All Newly Treated Patients
Switch/Augment to another SSRI/SNRI	0.75 (0.57, 0.98)^d	0.77 (0.56, 1.05)	0.97 (0.64, 1.47)

Switch/Augment to any antidepressant	0.94 (0.78, 1.13)	0.92 (0.75, 1.12)	1.02 (0.78, 1.35)

Discontinuation of SSRI/SNRI therapy	1.10 (1.01, 1.19)^c	1.07 (0.97, 1.18)	1.03 (0.91, 1.17)

Discontinuation of all antidepressants	1.10 (1.01, 1.20)^c	1.08 (0.97, 1.19)	1.02 (0.90, 1.17)

Adverse Events 12 Months Following Initiation	Adjusted Hazard Ratio		Change in Michigan vs. Indiana
	Policy vs. Pre-Policy Hazard (95% CI)
	Michigan (N=3,671)	Indiana (N=2,400)

All Events
Emergency Room	1.04 (0.95, 1.14)	1.09 (0.98, 1.21)	0.95 (0.83, 1.00)

Hospitalization	1.00 (0.88, 1.13)	0.90 (0.79, 1.04)	1.11 (0.92, 1.33)

Selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors only

Models controlled for age, gender, race, comorbidity

pre-policy: November 2000-August 2001; post-policy: March 2002 and December 2002

p<0.05